CLINICAL_TRIALS
trial_result
· 2018-11-02
Clinical Trial Update: A mGlu2/3 Agonist in the Treatment of PTSD [Phase 1]
Summary
Phase 1 clinical trial update of an mGlu2/3 agonist for post-traumatic stress disorder (PTSD) has terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NYU Langone Health | Conditions: Post-traumatic Stress Disorder | Phase 1 | Status: TERMINATED | Results posted: 2018-11-02